Literature DB >> 23324590

Evaluation of the overall IFN-γ and IL-17 pro-inflammatory responses after DNA therapy of tuberculosis.

Carlos R Zárate-Bladés1, Rodrigo F Rodrigues, Patricia R M Souza, Wendy M Rios, Luana S Soares, Rogério S Rosada, Izaíra T Brandão, Ana Paula Masson, Elaine M Floriano, Simone G Ramos, Celio L Silva.   

Abstract

Despite the enormous efforts displayed globally in the fight against tuberculosis, the disease incidence has modified slightly, which has led to a renewed interest in immunotherapy. In general, successful immunotherapeutic candidates against tuberculosis are agents that can trigger strong, specific pro-inflammatory responses, especially of the T-helper (Th) 1 pattern. However, how these pro-inflammatory agents effectively kill the bacteria without eliciting immunopathology is not well understood. We reasoned that, in addition to the specific immune response elicited by immunotherapy, the evaluation of the overall pro-inflammatory responses should provide additional and valuable information that will be useful in avoiding immunopathology. We evaluated the overall IFN-γ and IL-17 pro-inflammatory responses among CD4(+), CD8(+) and γδ T cells in the lungs of mice that were infected with M. tuberculosis and treated with a DNA vaccine in an immunotherapeutic regimen. Our results demonstrate that mice that effectively combat the pathogen develop a strong, specific Th1 immune response against the therapeutic antigen and have reduced lung inflammation, present in parallel a fine-tuning in the total IFN-γ- and IL-17-mediated immunity in the lungs. This modulation of the total immune response involves reducing the Th17 cell population, augmenting CD8(+) T cells that produce IFN-γ and increasing the total γδ T cell frequency. These results stress the importance of a broad evaluation of not only the specific immune response at the time to evaluate new immune interventional strategies against tuberculosis but also non-conventional T cells, such as γδ T lymphocytes.

Entities:  

Keywords:  DNA vaccination; Th1/Th17 responses; immunotherapy; inflammation; tuberculosis

Mesh:

Substances:

Year:  2013        PMID: 23324590      PMCID: PMC3899145          DOI: 10.4161/hv.23417

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  63 in total

1.  Experimental tuberculosis: designing a better model to test vaccines against tuberculosis.

Authors:  Denise Morais Fonseca; Rogério Silva Rosada; Marina Oliveira e Paula; Pryscilla Fanini Wowk; Luis Henrique Franco; Edson Garcia Soares; Célio Lopes Silva; Vânia Luiza Deperon Bonato
Journal:  Tuberculosis (Edinb)       Date:  2010-02-25       Impact factor: 3.131

2.  IL-17 production is dominated by gammadelta T cells rather than CD4 T cells during Mycobacterium tuberculosis infection.

Authors:  Euan Lockhart; Angela M Green; JoAnne L Flynn
Journal:  J Immunol       Date:  2006-10-01       Impact factor: 5.422

Review 3.  Tuberculosis: vaccines in the pipeline.

Authors:  Lan H Ly; David N McMurray
Journal:  Expert Rev Vaccines       Date:  2008-07       Impact factor: 5.217

Review 4.  Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis.

Authors:  John Stanford; Cynthia Stanford; John Grange
Journal:  Front Biosci       Date:  2004-05-01

5.  Pathological role of interleukin 17 in mice subjected to repeated BCG vaccination after infection with Mycobacterium tuberculosis.

Authors:  Andrea Cruz; Alexandra G Fraga; Jeffrey J Fountain; Javier Rangel-Moreno; Egídio Torrado; Margarida Saraiva; Daniela R Pereira; Troy D Randall; Jorge Pedrosa; Andrea M Cooper; António G Castro
Journal:  J Exp Med       Date:  2010-07-12       Impact factor: 14.307

Review 6.  Advances in immunotherapy for tuberculosis treatment.

Authors:  Gavin J Churchyard; Gilla Kaplan; Dorothy Fallows; Robert S Wallis; Philip Onyebujoh; Graham A Rook
Journal:  Clin Chest Med       Date:  2009-12       Impact factor: 2.878

7.  Comprehensive gene expression profiling in lungs of mice infected with Mycobacterium tuberculosis following DNAhsp65 immunotherapy.

Authors:  Carlos Rodrigo Zárate-Bladés; Vânia Luiza Deperon Bonato; Eduardo Lani Volpe da Silveira; Marina Oliveira e Paula; Cristina Moraes Junta; Paula Sandrin-Garcia; Ana Lúcia Fachin; Stephano Spanó Mello; Renato Sousa Cardoso; Fábio Cícero de Sá Galetti; Arlete Aparecida Martins Coelho-Castelo; Simone Gusmão Ramos; Eduardo Antonio Donadi; Elza Tiemi Sakamoto-Hojo; Geraldo Aleixo da Silva Passos; Celio Lopes Silva
Journal:  J Gene Med       Date:  2009-01       Impact factor: 4.565

Review 8.  The immunological life cycle of tuberculosis.

Authors:  Joel D Ernst
Journal:  Nat Rev Immunol       Date:  2012-07-13       Impact factor: 53.106

9.  Mycobacterium vaccae as adjuvant therapy to anti-tuberculosis chemotherapy in never-treated tuberculosis patients: a meta-analysis.

Authors:  Xiao-Yan Yang; Qun-Fei Chen; You-Ping Li; Si-Miao Wu
Journal:  PLoS One       Date:  2011-09-06       Impact factor: 3.240

10.  Potential of novel Mycobacterium tuberculosis infection phase-dependent antigens in the diagnosis of TB disease in a high burden setting.

Authors:  Novel N Chegou; Gillian F Black; Andre G Loxton; Kim Stanley; Paulin N Essone; Michel R Klein; Shreemanta K Parida; Stefan H E Kaufmann; T Mark Doherty; Annemieke H Friggen; Kees L Franken; Tom H Ottenhoff; Gerhard Walzl
Journal:  BMC Infect Dis       Date:  2012-01-20       Impact factor: 3.090

View more
  7 in total

1.  Immunotherapy of tuberculosis with Mycobacterium leprae Hsp65 as a DNA vaccine triggers cross-reactive antibodies against mammalian Hsp60 but not pathological autoimmunity.

Authors:  Nayara T S Doimo; Carlos R Zárate-Bladés; Rodrigo F Rodrigues; Cristiane Tefé-Silva; Marcele N S Trotte; Patrícia R M Souza; Luana S Soares; Wendy M Rios; Elaine M Floriano; Izaira T Brandão; Ana P Masson; Verônica Coelho; Simone G Ramos; Celio L Silva
Journal:  Hum Vaccin Immunother       Date:  2014-03-07       Impact factor: 3.452

2.  Mycobacterial Hsp65 antigen upregulates the cellular immune response of healthy individuals compared with tuberculosis patients.

Authors:  Pryscilla Fanini Wowk; Luís Henrique Franco; Denise Morais da Fonseca; Marina Oliveira Paula; Élcio Dos Santos Oliveira Vianna; Ana Paula Wendling; Valéria Maria Augusto; Silvana Maria Elói-Santos; Andréa Teixeira-Carvalho; Flávia Dias Coelho Silva; Solange Alves Vinhas; Olindo Assis Martins-Filho; Moisés Palaci; Célio Lopes Silva; Vânia Luiza Deperon Bonato
Journal:  Hum Vaccin Immunother       Date:  2017-01-06       Impact factor: 3.452

Review 3.  Autophagy in the fight against tuberculosis.

Authors:  Carla F Bento; Nuno Empadinhas; Vítor Mendes
Journal:  DNA Cell Biol       Date:  2015-01-21       Impact factor: 3.311

4.  Recombinant BCG Expressing LTAK63 Adjuvant induces Superior Protection against Mycobacterium tuberculosis.

Authors:  Ivan P Nascimento; Dunia Rodriguez; Carina C Santos; Eduardo P Amaral; Henrique K Rofatto; Ana P Junqueira-Kipnis; Eduardo D C Gonçalves; Maria R D'Império-Lima; Mario H Hirata; Celio L Silva; Nathalie Winter; Brigitte Gicquel; Kingston H G Mills; Mariagrazia Pizza; Rino Rappuoli; Luciana C C Leite
Journal:  Sci Rep       Date:  2017-05-18       Impact factor: 4.379

Review 5.  Host-targeted therapy for tuberculosis: Time to revisit the concept.

Authors:  Prabha Desikan; Aseem Rangnekar
Journal:  Indian J Med Res       Date:  2018-03       Impact factor: 2.375

Review 6.  Host immune responses to mycobacterial antigens and their implications for the development of a vaccine to control tuberculosis.

Authors:  Jae-Min Yuk; Eun-Kyeong Jo
Journal:  Clin Exp Vaccine Res       Date:  2014-06-20

Review 7.  Immunotherapeutic Activities of a DNA Plasmid Carrying the Mycobacterial hsp65 Gene (DNAhsp65).

Authors:  Celio Lopes Silva; Thiago Malardo; Aline Seiko Carvalho Tahyra
Journal:  Front Med Technol       Date:  2020-12-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.